Oral News and Research

RSS

New approach to make RNA vaccines easier to swallow

Like most vaccines, RNA vaccines have to be injected, which can be an obstacle for people who fear needles. Now, a team of MIT researchers has developed a way to deliver RNA in a capsule that can be swallowed, which they hope could help make people more receptive to them.

31 Jan 2022

3C-like protease inhibitor clinical candidate, S-217622, as a treatment for SARS-CoV-2

In a new study, a team of researchers discovered S-217622, a non-covalent SARS-CoV-2 3C-like protease (3CLpro) inhibitor clinical candidate for the treatment of COVID-19.

31 Jan 2022

Vaccine hypersensitivity in children

A new paper published in Pediatric Allergy and Immunity provides a useful overview of such reactions in relation to pediatric vaccines.

31 Jan 2022

Research shows minks mimic severe COVID-19 symptoms, including ARDS

Minks may be a suitable animal model for testing severe COVID-19 infections, finds a recent bioRxiv* preprint study. While mice and ferrets are used in preclinical severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is currently no model specific to severe disease.

30 Jan 2022

New study to explore the role of dentists in reducing obesity in the UK

A new study being led by Loughborough University will look at the role dentists can play in reducing obesity in the UK.

28 Jan 2022

Photobiomodulation may accelerate the healing of skin damage from radiation therapy

Light therapy may accelerate the healing of skin damage from radiation therapy by up to 50%, according to a recent University at Buffalo-led study.

27 Jan 2022

Researchers receive $3.7 million to identify reasons for higher rates of cancers, other diseases in HIV patients

About 1.2 million people with HIV in the United States live relatively normal lives with uncompromised immune systems and the virus medically controlled.

27 Jan 2022

Death rates from ovarian cancer are predicted to fall by 2022 in EU countries

Death rates from ovarian cancer are predicted to fall by 17% in the UK and by 7% in EU countries in 2022 compared to 2017, according to new research published in the leading cancer journal Annals of Oncology today (Wednesday).

27 Jan 2022

Regular physical activity lowers type 2 diabetes risk by changing the body's metabolite profile

Regular physical activity significantly changes the body's metabolite profile, and many of these changes are associated with a lower risk of type 2 diabetes, a new study from the University of Eastern Finland shows.

26 Jan 2022

Breast cancer drug shows promise in treating young infants with PIK3CA-related overgrowth spectrum

PIK3CA-related overgrowth spectrum (PROS) is a group of rare, incurable disorders caused by mutations in the PIK3CA gene that result in the malformation and overgrowth of various parts of the body.

26 Jan 2022

Oral polio vaccine could play a role against COVID-19

In a recent study posted to the medRxiv* preprint server, researchers performed an economic evaluation of the oral polio vaccine (OPV) to illustrate the potential non-specific (heterologous) effects (NSE) of live attenuated vaccines (LAVs).

25 Jan 2022

RUDN University dentist implements new approach to treating inflammation of periodontal tissues

A dentist from RUDN University implemented a new approach to treating of inflammation of tissues around dental root and root canal.

22 Jan 2022

Researchers call for more work to address unmet needs of women with Parkinson's disease

Researchers in a multi-institution study led by UCLA Health have identified several overlooked issues affecting women with Parkinson's Disease (PD) and call for more research, customized treatments, education and support to empower women living with this disease and to address their unmet medical needs.

22 Jan 2022

Novel compound found in mussels helps increase the durability of dental fillings

Leading researchers from the Faculty of Dentistry, the University of Hong Kong, Wuhan University, and the Peking University Shenzhen Hospital have found that a compound found in mussels helps increase the durability of a dental filling.

22 Jan 2022

Study shows monoclonal antibody and antiviral therapy are useful in preventing the severity of SARS-CoV-2 Omicron infection

In a new study, researchers assessed the efficacy of the FDA-approved therapeutic mAbs, as well as to small-molecule antiviral agents against the SARS-CoV-2 Omicron variant in Syrian hamsters.

21 Jan 2022

New opportunity to induce remission of peanut allergy in young children through oral immunotherapy

A clinical trial funded by the National Institutes of Health has found that giving peanut oral immunotherapy to highly peanut-allergic children ages 1 to 3 years safely desensitized most of them to peanut and induced remission of peanut allergy in one-fifth. The immunotherapy consisted of a daily oral dose of peanut flour for 2.5 years.

21 Jan 2022

Patient, beware: Some states still pushing ineffective covid antibody treatments

As the omicron variant completes its sweep across the U.S., states with scarce supplies of monoclonal antibody therapies continue to use two treatments that federal health officials warn no longer work against the highly contagious version of the virus that causes covid-19.

21 Jan 2022

Cannabidiol found to inhibit SARS-CoV-2 infection in human cells and mice

An interdisciplinary team of researchers from the University of Chicago has found evidence that cannabidiol (CBD), a product of the cannabis plant, can inhibit infection by SARS-CoV-2 in human cells and in mice.

21 Jan 2022

PAXLOVID shown to be highly effective against all SARS-CoV-2 variants

A recent study, currently available on bioRxiv* preprint server, shows that a novel protease inhibitor known as nirmatrelvir has potent activity against Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but also other variants evaluated in this paper – which supports its potential role in reducing the disease burden from coronavirus disease 2019 (COVID-19).

21 Jan 2022

The tetrapeptide tuftsin effectively impairs the binding of SARS-CoV-2 S1 to ACE2

In their recent study posted to the preprint server bioRxiv*, the researchers from China have shown that tuftsin, a natural phagocytosis-stimulating peptide, can effectively impair the binding of SARS-CoV-2 spike S1 subunit to ACE2 receptor in a dose-dependent manner and therefore can be considered a potential drug against SARS-CoV-2 infection.

20 Jan 2022

Oral News and Research

New approach to make RNA vaccines easier to swallow

3C-like protease inhibitor clinical candidate, S-217622, as a treatment for SARS-CoV-2

Vaccine hypersensitivity in children

Research shows minks mimic severe COVID-19 symptoms, including ARDS

New study to explore the role of dentists in reducing obesity in the UK

Photobiomodulation may accelerate the healing of skin damage from radiation therapy

Researchers receive $3.7 million to identify reasons for higher rates of cancers, other diseases in HIV patients

Death rates from ovarian cancer are predicted to fall by 2022 in EU countries

Regular physical activity lowers type 2 diabetes risk by changing the body's metabolite profile

Breast cancer drug shows promise in treating young infants with PIK3CA-related overgrowth spectrum

Oral polio vaccine could play a role against COVID-19

RUDN University dentist implements new approach to treating inflammation of periodontal tissues

Researchers call for more work to address unmet needs of women with Parkinson's disease

Novel compound found in mussels helps increase the durability of dental fillings

Study shows monoclonal antibody and antiviral therapy are useful in preventing the severity of SARS-CoV-2 Omicron infection

New opportunity to induce remission of peanut allergy in young children through oral immunotherapy

Patient, beware: Some states still pushing ineffective covid antibody treatments

Cannabidiol found to inhibit SARS-CoV-2 infection in human cells and mice

PAXLOVID shown to be highly effective against all SARS-CoV-2 variants

The tetrapeptide tuftsin effectively impairs the binding of SARS-CoV-2 S1 to ACE2

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News